Abstract
Rasd2 is a thyroid hormone target gene, which encodes for a GTP-binding protein enriched in the striatum where, among other functions, it modulates dopaminergic neurotransmission. Here we report that human RASD2 mRNA is abundant in putamen, but it also occurs in the cerebral cortex, with a distinctive expression pattern that differs from that present in rodents. Consistent with its localization, we found that a genetic variation in RASD2 (rs6518956) affects postmortem prefrontal mRNA expression in healthy humans and is associated with phenotypes of relevance to schizophrenia, including prefrontal and striatal grey matter volume and physiology during working memory, as measured with magnetic resonance imaging. Interestingly, quantitative real-time PCR analysis indicated that RASD2 mRNA is slightly reduced in postmortem prefrontal cortex of patients with schizophrenia. In the attempt to uncover the neurobiological substrates associated with Rasd2 activity, we used knockout mice to analyze the in vivo influence of this G-protein on the prepulse inhibition of the startle response and psychotomimetic drug-related behavioral response. Data showed that Rasd2 mutants display deficits in basal prepulse inhibition that, in turn, exacerbate gating disruption under psychotomimetic drug challenge. Furthermore, we documented that lack of Rasd2 strikingly enhances the behavioral sensitivity to motor stimulation elicited by amphetamine and phencyclidine. Based on animal model data, along with the finding that RASD2 influences prefronto-striatal phenotypes in healthy humans, we suggest that genetic mutation or reduced levels of this G-protein might have a role in cerebral circuitry dysfunction underpinning exaggerated psychotomimetic drugs responses and development of specific biological phenotypes linked to schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234–258.
Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J et al (2014). The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 5: 47.
Consortium EP (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57–74.
Costa-Mattioli M, Monteggia LM (2013). mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci 16: 1537–1543.
DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW et al (2002). A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 803–812.
Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131–137.
Errico F, Santini E, Migliarini S, Borgkvist A, Centonze D, Nasti V et al (2008). The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. Mol Cell Neurosci 37: 335–345.
Falk JD, Vargiu P, Foye PE, Usui H, Perez J, Danielson PE et al (1999). Rhes: a striatal-specific Ras homolog related to Dexras1. J Neurosci Res 57: 782–788.
Gargiulo PA, Landa De Gargiulo AI (2014). Glutamate and modeling of schizophrenia symptoms: review of our findings: 1990-2014. Pharmacol Rep 66: 343–352.
Ghiglieri V, Napolitano F, Pelosi B, Schepisi C, Migliarini S, Di Maio A et al (2015). Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion. Sci Rep 5: 10933.
Goldman-Rakic PS (1995). Cellular basis of working memory. Neuron 14: 477–485.
Gottesmann C (2003). Inhibitory processes in the brain. Drug Discov Today 8: 1020–1021.
Harrison LM, Lahoste GJ (2013). The role of Rhes, Ras homolog enriched in striatum, in neurodegenerative processes. Exp Cell Res 319: 2310–2315.
Harrison LM, LaHoste GJ (2006). Rhes, the Ras homolog enriched in striatum, is reduced under conditions of dopamine supersensitivity. Neuroscience 137: 483–492.
Harrison LM, Lahoste GJ, Ruskin DN (2008). Ontogeny and dopaminergic regulation in brain of Ras homolog enriched in striatum (Rhes). Brain Res 1245: 16–25.
Harrison LM, Muller SH, Spano D (2013). Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum. Neuroscience 236: 21–30.
Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78: 69–108.
Jonas RK, Montojo CA, Bearden CE (2014). The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. Biol Psychiatry 75: 351–360.
Jones CA, Watson DJ, Fone KC (2011). Animal models of schizophrenia. Br J Pharmacol 164: 1162–1194.
Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF et al (2007). Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology 32: 577–588.
Kulkarni J, Hayes E, Gavrilidis E (2012). Hormones and schizophrenia. Curr Opin Psychiatry 25: 89–95.
Kumari V (2011). Sex differences and hormonal influences in human sensorimotor gating: implications for schizophrenia. Curr Top Behav Neurosci 8: 141–154.
Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, Thompson LM et al (2015). Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. Neuron 85: 303–315.
Liu YL, Fann CS, Liu CM, Chen WJ, Wu JY, Hung SI et al (2008). RASD2, MYH9, and CACNG2 genes at chromosome 22q12 associated with the subgroup of schizophrenia with non-deficit in sustained attention and executive function. Biol Psychiatry 64: 789–796.
Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94: 507–514.
Manzano J, Morte B, Scanlan TS, Bernal J (2003). Differential effects of triiodothyronine and the thyroid hormone receptor beta-specific agonist GC-1 on thyroid hormone target genes in the b ain. Endocrinology 144: 5480–5487.
Martino D, Di Giorgio A, D'Ambrosio E, Popolizio T, Macerollo A, Livrea P et al (2011). Cortical gray matter changes in primary blepharospasm: a voxel-based morphometry study. Mov Disord 26: 1907–1912.
Napolitano F, Bonito-Oliva A, Federici M, Carta M, Errico F, Magara S et al (2010). Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. J Neurosci 30: 11043–11056.
Pascoli V, Valjent E, Corbille AG, Corvol JC, Tassin JP, Girault JA et al (2005). cAMP and extracellular signal-regulated kinase signaling in response to d-amphetamine and methylphenidate in the prefrontal cortex in vivo: role of beta 1-adrenoceptors. Mol Pharmacol 68: 421–429.
Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I (1999). Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92: 601–611.
Potash JB, Zandi PP, Willour VL, Lan TH, Huo Y, Avramopoulos D et al (2003). Suggestive linkage to chromosomal regions 13q31 and 22q12 in families with psychotic bipolar disorder. Am J Psychiatry 160: 680–686.
Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA (2001). Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 21: 305–313.
Sciamanna G, Napolitano F, Pelosi B, Bonsi P, Vitucci D, Nuzzo T et al (2015). Rhes regulates dopamine D2 receptor transmission in striatal cholinergic interneurons. Neurobiol Dis 78: 146–161.
Seeman P (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci 5: 24–29.
Spano D, Branchi I, Rosica A, Pirro MT, Riccio A, Mithbaokar P et al (2004). Rhes is involved in striatal function. Mol Cell Biol 24: 5788–5796.
Subramaniam S, Mealer RG, Sixt KM, Barrow RK, Usiello A, Snyder SH (2010). Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9. J Biol Chem 285: 20428–20432.
Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, Barrow R et al (2012). Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci 15: 191–193.
Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M et al (2003). Diverse psychotomimetics act through a common signaling pathway. Science 302: 1412–1415.
Svensson TH (2000). Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31: 320–329.
Swerdlow NR, Geyer MA (1998). Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24: 285–301.
Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R et al (2008). Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 118: 2200–2208.
Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007). Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33: 69–94.
Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al (2000). Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408: 199–203.
Vallortigara J, Alfos S, Micheau J, Higueret P, Enderlin V (2008). T3 administration in adult hypothyroid mice modulates expression of proteins involved in striatal synaptic plasticity and improves motor behavior. Neurobiol Dis 31: 378–385.
Vallortigara J, Chassande O, Higueret P, Enderlin V (2009). Thyroid hormone receptor alpha plays an essential role in the normalisation of adult-onset hypothyroidism-related hypoexpression of synaptic plasticity target genes in striatum. J Neuroendocrinol 21: 49–56.
Vargiu P, De Abajo R, Garcia-Ranea JA, Valencia A, Santisteban P, Crespo P et al (2004). The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors. Oncogene 23: 559–568.
Vargiu P, Morte B, Manzano J, Perez J, de Abajo R, Gregor Sutcliffe J et al (2001). Thyroid hormone regulation of rhes, a novel Ras homolog gene expressed in the striatum. Brain Res Mol Brain Res 94: 1–8.
Vauquelin G, Bostoen S, Vanderheyden P, Seeman P (2012). Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 385: 337–372.
Wenthur CJ, Bennett MR, Lindsley CW (2014). Classics in chemical neuroscience: fluoxetine (Prozac). ACS Chem Neurosci 5: 14–23.
Xu R, Hranilovic D, Fetsko LA, Bucan M, Wang Y (2002). Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol Psychiatry 7: 1075–1082.
Acknowledgements
We are grateful to Neurodegenerative Diseases Brain Bank (King’s College London, UK) for providing us postmortem prefrontal cortex samples. We thank Dr P Krashia and S Subramanian for his critical discussion and M Squillace, G Aceto, T Nuzzo, and V Lucignano for their excellent technical support. We also thank R Masellis, P Selvaggi, R Romano, and S Trizio for their contribution to data analysis.
Author contributions
AU and AB designed the research and approved the final version of the paper. ADM, DV, FN, ADG, MP, VM, BP, FE, MTA, BG, LF, and PT performed the research. ADG, GB, FE, AU, MP, and AB analyzed the data. DV, FN, ADG, AB, and AU wrote the paper.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
Rights and permissions
About this article
Cite this article
Vitucci, D., Di Giorgio, A., Napolitano, F. et al. Rasd2 Modulates Prefronto-Striatal Phenotypes in Humans and ‘Schizophrenia-Like Behaviors’ in Mice. Neuropsychopharmacol 41, 916–927 (2016). https://doi.org/10.1038/npp.2015.228
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2015.228
This article is cited by
-
Matrix Metalloproteinase 1 as a Marker of Tonsil-Derived Mesenchymal Stem Cells to Assess Bone Marrow Cell Migration
Tissue Engineering and Regenerative Medicine (2023)
-
Patterns of neuronal Rhes as a novel hallmark of tauopathies
Acta Neuropathologica (2021)
-
The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior
Translational Psychiatry (2020)
-
Genome-wide DNA methylation meta-analysis in the brains of suicide completers
Translational Psychiatry (2020)
-
The striatal-enriched protein Rhes is a critical modulator of cocaine-induced molecular and behavioral responses
Scientific Reports (2019)